Insulet Lawsuit Loss, Deepening Capital Erosion, Rising Going Concern Uncertainty

Litigation risk: US court ruled trade secret theft by Insulet, imposing worldwide sales ban (6-month exception for existing EU/Korea patients) and $59.4 million damages. UPC also banned sales. Appeal ongoing.
Litigation provision: ~109.2 billion won recognized (consolidated).
Revenue collapse: Q1 2026 consolidated revenue 97.9 million won (99% drop from 969.8 million in Q1 2025). New sales halted, existing customers lost due to lawsuit.
Net loss: 9.1 billion won loss sustained (consolidated).
Capital impairment: Consolidated equity -153.8 billion won (full impairment). Debt ratio incalculable.
Liquidity crisis: Current liabilities exceed current assets by 166.5 billion won. Cash only 0.99 billion won.
Going concern uncertainty: Auditor's note raises material doubt; self-rescue plans (asset sales, equity offering) needed.
Asset seizures: Insulet executed multiple provisional seizures on company deposits, real estate, patents, etc.

ADVERTISEMENT (250px+)